BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -
Organisms have unique DNA and RNA sequences or fingerprints. When a PNA probe designed to react with a specific RNA or DNA target sequence, for example a viral sequence from HIV, is mixed with a test sample the probe binds only if the virus is present.
By incorporating a reporter label within the PNA probe, the binding can be detected thus indicating the presence of the virus.
Dr. Jack Johansen, the president and CEO of Boston Probes believes, "PNA probes are dramatically superior to conventional oligonucleotide probes for detecting RNA and DNA because they are so discriminating with regard to the sequence of the target.
PNAs also bind more avidly and faster to RNA and DNA providing more robust and speedier assays." PNAs have been shown to greatly improve current DNA probe technologies which require long reaction times and often a complex series of steps for their use. He continues, "The knowledge gained from the Human Genome Project and sequencing of microorganisms is paving the way for explosive growth in the area of probe-based diagnostics.
We're convinced that our PNA probes will replace DNA probes in many assays and that PNA will accelerate the acceptance and use of probe tests in all application areas." BPI's founders and scientific staff have extensive experience in the synthesis, analysis and use of PNA and were instrumental in the development of the technology.
BPI has a license to use PNA probes for detection of human infectious diseases, genetic diseases and cancers. The company also has rights to use PNA for detection of microorganisms in foods, beverages, water, the environment and industrial processes such as pharmaceutical manufacturing. In addition to its own product development, the company intends to enter exclusive strategic alliance/distribution agreements over the coming year and is entertaining discussions with potential partners at this time. Companies interested in access to PNA for diagnostic applications should contact BPI at the number listed below.
BPI was established by DAKO A/S, Copenhagen Denmark, a world leader in the production and sales of antibodies to the research and diagnostic markets. DAKO views BPI and PNA as a strategic complement to its dominant position in antibody technologies.
CONTACT: Boston Probes Inc. Dr. James Coull, 617/271-1100 ext. 223
Copyright (c) 1996/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
960926
BW960921
Copyright © 1996 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .